Memo Therapeutics

ETH spin-off Memo Therapeutics has developed a novel technology for rapid discovery of antibodies. Current methods to identify antibodies for drug development are based on investigating individual antibodies at a time and are very cost and time-intensive. Instead of focussing on one antibody at a time, Memo Therapeutics’ solution makes an individual’s entire antibody repertoire searchable and repeatedly accessible for drug discovery. This novel approach is 100-1000 times more efficient in finding rare antibodies for drug development.
Karsten Fischer about Verve Ventures
Verve Ventures has tremendously helped us in our financing round and realized a very broad campaign increasing the awareness for our company drastically.
Founders / Management Christoph Esslinger
Sectors Health & Bio, Biotechnology, Vaccines
Located in Schlieren - Switzerland
Co-Investors Zürcher Kantonalbank, Redalpine, Schroder Adveq
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.